Immunocore (NASDAQ:IMCR) Stock Rating Lowered by Wall Street Zen

Immunocore (NASDAQ:IMCR) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

IMCR has been the subject of several other research reports. Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Immunocore in a report on Monday, April 20th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunocore has an average rating of “Hold” and a consensus price target of $56.71.

Immunocore Trading Down 3.5%

Shares of IMCR stock opened at $33.77 on Tuesday. Immunocore has a fifty-two week low of $27.56 and a fifty-two week high of $40.71. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.15 and a current ratio of 4.18. The stock’s fifty day moving average is $30.84 and its two-hundred day moving average is $31.30. The firm has a market capitalization of $1.72 billion, a P/E ratio of -61.40 and a beta of 0.73.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.51. The business had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 earnings per share. Research analysts expect that Immunocore will post 0.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunocore

A number of institutional investors have recently bought and sold shares of IMCR. Leonteq Securities AG purchased a new stake in shares of Immunocore in the 4th quarter valued at approximately $30,000. Harbour Investments Inc. increased its position in shares of Immunocore by 60.2% during the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after purchasing an additional 388 shares during the last quarter. Rockefeller Capital Management L.P. acquired a new position in Immunocore in the fourth quarter valued at about $47,000. Arax Advisory Partners raised its stake in shares of Immunocore by 302.9% in the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after acquiring an additional 1,042 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of Immunocore by 202.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock valued at $61,000 after acquiring an additional 1,286 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.